Your browser doesn't support javascript.
loading
Effective management of severe cutaneous mastocytosis in young children with omalizumab (Xolair® ).
Hughes, J D M; Olynyc, T; Chapdelaine, H; Segal, L; Miedzybrodzki, B; Ben-Shoshan, M.
Afiliación
  • Hughes JDM; University of Ottawa - Department of Medicine, Ottawa, Ontario, Canada.
  • Olynyc T; Department of Medicine, The Ottawa Hospital, Ottawa, Ontario, Canada.
  • Chapdelaine H; Department of Medicine, Centre Hospitalier Universitaire de Montreal, Montreal, Quebec, Canada.
  • Segal L; Department of Medicine, Community Pediatrics, University of Ottawa, Ottawa, Ontario, Canada.
  • Miedzybrodzki B; Department of Pediatrics, Division of Allergy and Clinical Immunology and Dermatology, Department of Pediatrics, Montreal Children's Hospital, Montreal, Quebec, Canada.
  • Ben-Shoshan M; Department of Pediatrics, Division of Allergy and Clinical Immunology and Dermatology, Department of Pediatrics, Montreal Children's Hospital, Montreal, Quebec, Canada.
Clin Exp Dermatol ; 43(5): 573-576, 2018 Jul.
Article en En | MEDLINE | ID: mdl-29451318
Omalizumab (Xolair® ) is an anti-IgE monoclonal antibody, which may benefit adults with systemic mastocytosis. We report effective treatment with omalizumab in two toddlers with severe diffuse cutaneous mastocytosis. Our cases offer preliminary evidence to support the safe use of omalizumab in paediatric patients with cutaneous mastocytosis.
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Antialérgicos / Mastocitosis Cutánea / Omalizumab Límite: Child, preschool / Humans / Male Idioma: En Revista: Clin Exp Dermatol Año: 2018 Tipo del documento: Article País de afiliación: Canadá
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Antialérgicos / Mastocitosis Cutánea / Omalizumab Límite: Child, preschool / Humans / Male Idioma: En Revista: Clin Exp Dermatol Año: 2018 Tipo del documento: Article País de afiliación: Canadá